Enanta Pharmaceuticals, Inc. (ENTA) vs Larimar Therapeutics, Inc. (LRMR)

Enanta Pharmaceuticals, Inc. and Larimar Therapeutics, Inc. are both Biotechnology companies. Enanta Pharmaceuticals, Inc. and Larimar Therapeutics, Inc. are of similar size ($349.5M and $344.9M). Larimar Therapeutics, Inc. has the higher net margin (0.00% vs −96.9%) and the higher return on invested capital (0.00% vs 0.00%). Across the 12 metrics below, Enanta Pharmaceuticals, Inc. leads on 6 and Larimar Therapeutics, Inc. on 6.

Valuation

Metric ENTA LRMR Biotechnology median
P/E n/m n/m 7.88
P/S 5.30 n/m 11.47
P/B 3.42 2.51 2.52
Price to free cash flow n/m n/m 21.16
EV/EBITDA n/m n/m 0.74
EV/Sales 2.39 n/m 10.73
Earnings yield (20.29%) (63.31%) (28.84%)
Free cash flow yield (10.69%) (48.79%) (23.03%)

Profitability

Metric ENTA LRMR Biotechnology median
Gross margin 100.00% 0.00% 65.16%
Operating margin (89.99%) 0.00% 0.00%
Net margin (96.89%) 0.00% 0.00%
Free cash flow margin (56.60%) 0.00% 0.00%
Return on equity (70.12%) (138.41%) (57.72%)
Return on assets (21.15%) (108.53%) (49.22%)
Return on invested capital 0.00% 0.00% 0.00%

Growth

Metric ENTA LRMR Biotechnology median
Revenue growth (TTM) 0.70% — 5.64%
EPS growth (last fiscal year) 29.93% (71.97%) —
Revenue growth, 5-year CAGR (11.81%) — 8.40%
Net income growth, 5-year CAGR 0.00% 0.00% 0.00%

Health

Metric ENTA LRMR Biotechnology median
Debt to equity 0.00 0.00 0.00
Current ratio 3.76 4.70 4.73
Net debt to EBITDA 2.35 0.79 0.96

Dividend

Metric ENTA LRMR Biotechnology median
Dividend yield — — 2.10%
Payout ratio 0.00 0.00 0.00

Size

Metric ENTA LRMR Biotechnology median
Market cap 349.50m 344.89m 162.10m

Compare with another peer

Any metric, up to five companies and an Excel export Powerpack